Paperbase

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection

Hervas-Stubbs, S. Majlessi, L. Simsova, M. Morova, J. Rojas, M. J. Nouze, C. Brodin, P. Sebo, P. Leclerc, C.

Infection and Immunity, 2006

https://doi.org/10.1128/iai.02086-05

Priscille Brodin

Brodin Priscille

ORCID: 0000-0003-0991-7344

Email: priscille.brodin@inserm.fr

How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011

Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.

Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364

Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z

Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535

Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619

Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009

Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297

2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163

Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650

High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016

High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114

Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b

Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040

Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022

A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648

Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779

Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u

The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573

Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675

Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a

High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023

Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0

High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100

High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044

Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583

High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645

Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507

Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033

Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062

Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064

Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794

Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006

Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006

High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05

Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06

Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009

Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0

Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049

Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541

Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468

ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0

CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859

A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x

6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322

Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b

Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681

Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2

Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831

Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029

A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091

Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125

Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025

Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086

Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18

The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4

Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030

Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101

Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129

A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627

Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360

Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316

Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378

Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902

Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13

Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18

A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J

Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516

Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127

Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277

Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224

Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085

IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551

Worms' Antimicrobial Peptides. 10.3390/md17090512

T(oo)bAd. 10.1038/s41589-019-0347-x

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38

Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570

Cell microbiology interview 10.1111/cmi.13288

Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505

Nathalie deboosere

deboosere Nathalie

ORCID: 0000-0002-2873-5485

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. 10.3390/toxins9070227

Phenotypic assays for Mycobacterium tuberculosis infection. 10.1002/cyto.a.23129

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. 10.1021/acschembio.7b00091

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619

A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114

Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces. 10.1016/j.fm.2012.04.007

Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR. 10.1016/j.jviromet.2011.10.013

Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce. 10.1016/j.ijfoodmicro.2011.08.011

Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens. 10.1016/j.jviromet.2011.06.002

Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water. 10.1128/aem.02484-10

A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries. 10.1016/j.fm.2010.05.018

Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment. 10.1016/j.watres.2010.01.013

Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables. 10.1016/j.ijfoodmicro.2005.11.007

Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system. 10.1016/j.ijfoodmicro.2003.10.015

Host-pathogen systems for early drug discovery against tuberculosis. 10.1016/j.mib.2017.11.017

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. 10.1073/pnas.1707840114

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. 10.1038/s41598-017-11843-4

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages. 10.1016/j.chom.2017.07.020

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-017-05453-3

Host-directed therapies offer novel opportunities for the fight against tuberculosis. 10.1016/j.drudis.2017.05.005

Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs. 10.1016/j.ijpharm.2017.05.030

Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. 10.3389/fcimb.2017.00137

Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. 10.2217/nnm-2016-0364

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. 10.1126/science.aag1006

How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. 10.1007/s00401-016-1652-z

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. 10.1016/j.str.2016.07.009

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. 10.1007/s00705-016-2771-5

[Mycolactone: the amazing analgesic mycobacterial toxin]. 10.1051/medsci/20163202007

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. 10.1039/c5ob02630j

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. 10.1128/jvi.01473-15

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083

Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. 10.1371/journal.ppat.1004650

[High content screening in chemical biology: overview and main challenges]. 10.1051/medsci/20153102016

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. 10.1007/978-1-4939-2450-9_24

2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. 10.1021/cb5007163

High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. 10.1128/aac.03705-14

Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 10.1016/j.cell.2014.04.040

Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. 10.1021/jm500422b

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262

The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. 10.1371/journal.pone.0047573

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g

Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200825u

A novel specific edge effect correction method for RNA interference screenings. 10.1093/bioinformatics/btr648

Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. 10.1371/journal.pone.0026675

High-content screening in infectious diseases. 10.1016/j.cbpa.2011.05.023

Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200076a

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38

High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. 10.1371/journal.ppat.1001100

High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. 10.4155/fmc.10.223

Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ. 10.1099/mic.0.038133-0

High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. 10.1371/journal.ppat.1000645

Systematic genetic nomenclature for type VII secretion systems. 10.1371/journal.ppat.1000507

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. 10.1016/j.biomaterials.2009.09.044

Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. 10.1126/science.1171583

Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure. 10.1177/1087057108328762

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. 10.1128/jb.00469-07

[Aquatic insects and transmission of Mycobacterium ulcerans]. 10.1051/medsci/20072367572

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. 10.1371/journal.ppat.0030062

Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. 10.1371/journal.pmed.0040064

Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. 10.1016/j.bmc.2006.12.009

Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. 10.1128/jb.00631-06

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. 10.1128/iai.02086-05

Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. 10.1016/j.bmc.2006.03.033

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. 10.1128/iai.74.4.2128-2137.2006

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. 10.1128/iai.74.1.88-98.2006

Tuberculosis: from genome to vaccine. 10.1586/14760584.4.4.541

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. 10.1099/mic.0.27799-0

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009

ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. 10.1086/421468

Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. 10.1128/iai.72.4.2170-2176.2004

CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. 10.1128/iai.71.12.7173-7177.2003

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. 10.1038/nm859

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. 10.1046/j.1365-2958.2002.03237.x

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. 10.1128/iai.70.10.5568-5578.2002

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. 10.1021/bi015732y

IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Sandra Hervas-Stubbs

Hervas-Stubbs Sandra

ORCID: 0000-0003-3391-1516

https://cima.unav.edu/en/investigacion/programas-transversales/inmunologia-inmunoterapia/terapia-celular-adoptiva

Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice 10.3389/fimmu.2018.00068

Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor 10.18632/oncotarget.17845

Expansion of Tumor-Infiltrating CD8(+) T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy 10.1158/0008-5472.CAN-17-0236

IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination 10.18632/oncotarget.13736

Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine 10.1371/journal.pone.0161216

Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy 10.18632/oncotarget.6608

Mitochondrial respiratory-chain adaptations in macrophages contribute to antibacterial host defense 10.1038/ni.3509

CD8(+) T cells undergo activation and programmed death-1 repression in the liver of aged Ae2(a,b)(-/-) mice favoring autoimmune cholangitis 10.18632/oncotarget.5665

Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression 10.1038/gt.2015.64

Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation 10.4049/jimmunol.1402997

Strict Requirement for Vector-Induced Type I Interferon in Efficacious Antitumor Responses to Virally Encoded IL12 10.1158/0008-5472.CAN-13-3356

Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver 10.1111/liv.12571

Anion exchanger 2 is critical for CD8+T cells to maintain pHi homeostasis and modulate immune responses 10.1002/eji.201344218

Antigen Targeting to CD11b(+) Dendritic Cells in Association with TLR4/TRIF Signaling Promotes Strong CD8(+) T Cell Responses 10.4049/jimmunol.1302974

Conventional but Not Plasmacytoid Dendritic Cells Foster the Systemic Virus-Induced Type I IFN Response Needed for Efficient CD8 T Cell Priming 10.4049/jimmunol.1301440

Elucidating Sources and Roles of Granzymes A and B during Bacterial Infection and Sepsis 10.1016/j.celrep.2014.06.012

Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein 10.1158/0008-5472.CAN-12-2660

Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model 10.1158/1078-0432.CCR-13-1189

Eradication of Liver-Implanted Tumors by Semliki Forest Virus Expressing IL-12 Requires Efficient Long-Term Immune Responses 10.4049/jimmunol.1201791

The immunological profile of tumor-bearing animals determines the outcome of cancer immunotherapy 10.4161/onci.24499

Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma 10.1158/1538-7445.AM2013-LB-330

CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy 10.4049/jimmunol.1102495

Evaluation of Monocytes as Carriers for Armed Oncolytic Adenoviruses in Murine and Syrian Hamster Models of Cancer 10.1089/hum.2012.043

Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12 10.1038/mt.2072.56

Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy 10.1371/journal.pone.0052370

Synergistic Effect of Thrombin and CD40 Ligand on Endothelial Matrix Metalloproteinase-10 Expression and Microparticle Generation In Vitro and In Vivo 10.1161/ATVBAHA.112.248773

The HIF-1 alpha hypoxia response in mouse tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy 10.1158/1538-7445.AM2011-3538

The HIF-1α hypoxia response in tumor-infi ltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy 10.1158/2159-8290.CD-11-0314

Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates 10.1186/1479-5876-10-122

Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes 10.1158/0008-5472.CAN-10-1733

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment ofactivated T lymphocytes 10.1158/1538-7445.AM2011-4740

Carcinoma-Derived Interleukin-8 Disorients Dendritic Cell Migration Without Impairing T-Cell Stimulation 10.1371/journal.pone.0017922

CD8 T cell priming in the presence of IFN alpha improves memory differentiation and the efficacy of adoptive immunotherapy 10.1016/j.cyto.2011.07.069

Dendritic Cells Take up and Present Antigens from Viable and Apoptotic Polymorphonuclear Leukocytes 10.1371/journal.pone.0029300

Direct Effects of Type I Interferons on Cells of the Immune System 10.1158/1078-0432.CCR-10-1114

Immunological effects of gene transfer with the sushi domain of IL-15R alpha and a chimeric protein consisting of IL-15 fused to apolipoprotein A-1 10.1016/j.cyto.2011.07.245

Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy 10.1002/ijc.25333

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice 10.1136/gut.2010.211722

Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients 10.4049/jimmunol.1102209

Polyubiquitin K63-related CD137 signalsomes in T cells stimulated with agonist anti-CD137 monoclonal antibodies 10.1158/1538-7445.AM2011-4567

Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo 10.1002/ijc.25681

Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells 10.1007/s00262-010-0888-z

Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α 10.1002/eji.201040523

Effects of IFN-alpha as a signal-3 cytokine on human naive and antigen-experienced CD8(+) T cells 10.1002/eji.201040664

Intensive Pharmacological Immunosuppression Allows for Repetitive Liver Gene Transfer With Recombinant Adenovirus in Nonhuman Primates 10.1038/mt.2009.312

Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo 10.1038/gt.2009.139

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ 10.1007/s00262-010-0846-9

Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? 10.2217/imt.09.51

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb 10.1002/eji.200838958

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes 10.1038/sj.bjc.6604965

PET imaging of thymidine kinase gene expression in the liver of non-human primates following systemic delivery of an adenoviral vector 10.1038/gt.2008.122

Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic 10.1111/j.1467-7652.2008.00338.x

Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells 10.1038/gt.2008.4

Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies 10.1016/j.tips.2008.05.005

Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma 10.1158/1078-0432.CCR-08-0285

Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer 10.1517/14712598.7.5.599

Immunostimulatory monoclonal antibodies for cancer therapy 10.1038/nrc2051

Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN (vol 178, pg 2361, 2007) 10.4049/jimmunol.178.10.6653

Insect baculoviruses strongly potentiate adaptive immune responses by inducing type IIFN 10.4049/jimmunol.178.4.2361

Interferon-producing killer dendritic cells and natural killer cells response to interleukin-15 liver gene transfer 10.1016/j.cyto.2007.07.111

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ 10.1002/ijc.22795

The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo 10.4049/jimmunol.178.2.748

TLR3 ligand stimulates fully functional memory CD8(+) T cells in the absence of CD4(+) T-cell help 10.1182/blood-2006-10-053256

High Frequency of CD4+ T Cells Specific for the TB10.4 Protein Correlates with Protection against Mycobacterium tuberculosis Infection 10.1128/IAI.02086-05

Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena 10.1158/1078-0432.CCR-06-0314

Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication 10.1016/j.ymthe.2006.02.015

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death 10.1084/jem.20050915

Cross-priming of T cell responses by synthetic microspheres carrying a CD8(+) T cell epitope requires an adjuvant signal 10.4049/jimmunol.174.6.3432

Induction of neutralizing antibodies by a tobacco chloroplast-derived vaccine based on a B cell epitope from canine parvovirus 10.1016/j.virol.2005.08.009

High-yield expression of a viral peptide animal vaccine in transgenic tobacco chloroplasts 10.1046/j.1467-7652.2004.00057.x

Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12 10.1128/JVI.75.19.9068-9076.2001

T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine 10.1016/S0168-8278(01)00063-0

Gene gun immunization effectively protects woodchucks from woodchuck hepatitis virus (WHV) infection 10.1016/S0168-8278(00)80836-3

Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection 10.1016/s0168-8278(97)80090-6

Simple strategy to induce antibodies of distinct specificity: Application to the mapping of gp120 and inhibition of HIV‐1 infectivity 10.1002/eji.1830250403

OVERCOMING CLASS II-LINKED NONRESPONSIVENESS TO HEPATITIS-B VACCINE 10.1016/0264-410x(94)90026-4

PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas 10.1182/blood.2018889931

Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity 10.3390/biomedicines8120562

Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8(+)T Cells 10.1016/j.ccell.2019.10.006

Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma 10.1016/j.jvir.2019.02.023

Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb 10.1186/2051-1426-1-3

Absence of surface expression of CD137 (4-1BB) on Myeloid-derived suppressor cells 10.1016/S0213-9626(07)70081-1

In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study'TIM3 Aptamers Binding 10.1038/mtna.2016.84

International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010 10.1007/s00262-011-1000-z

Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies 10.3389/fimmu.2019.02990

Interferon producing killer dendritic cells (IKDC): A matter of controversy 10.1016/S0213-9626(10)70010-X

Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic semliki forest virus encoding IL-12 10.1038/mt.2012.56

Interleukin-15 in gene therapy of cancer 10.2174/156652313804806561

Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses 10.1016/j.ymthe.2019.09.016

Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions 10.1186/s12974-019-1628-8

The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer 10.1080/2162402X.2017.1409321

Inflammation and immunity in ovarian cancer 10.1016/j.ejcsup.2019.12.002

Polly Matzinger's "danger model" finds its predicted danger-denoting self moieties 10.1016/S0213-9626(08)70068-4

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens 10.1136/jitc-2020-000704

The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1⁺ tumour-infiltrating lymphocytes 10.1038/s41416-020-01218-4

Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4–induced M2 macrophage polarization 10.1096/fj.201801563R

High-yield expression of a viral peptide animal vaccine in transgenic tobacco chloroplasts 10.1111/j.1467-7652.2004.00057.x

The HIF-1 alpha hypoxia response in mouse tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy 10.1158/1538-7445.AM2012-3538

Interleukin-15 in Gene Therapy of Cancer 10.2174/1566523211313010003

Role of IL12 in genetic immunization against WHV-core antigen: induction of TH1 immune responses and protection against woodchuck hepatitis virus (WHV) 10.1016/S0168-8278(01)81713-X

Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8+T cells 10.1158/1538-7445.SABCS18-2331

Preselecting tumour-infiltrating lymphocyte subsets to implement adoptive immunotherapy in ovarian cancer 10.1093/ANNONC/MDZ250.034

Long Noncoding RNA EGOT Responds to Stress Signals to Regulate Cell Inflammation and Growth 10.4049/jimmunol.1900776

Advances in immunotherapy for hepatocellular carcinoma 10.1038/s41575-021-00438-0

Adenovirus-Mediated Inducible Expression of a PD-L1 Blocking Antibody in Combination with Macrophage Depletion Improves Survival in a Mouse Model of Peritoneal Carcinomatosis 10.3390/ijms22084176

Peter SEBO

SEBO Peter / Peter SEBO

ORCID: 0000-0002-9755-7715

Pore-formation by adenylate cyclase toxoid activates dendritic cells to prime CD8⁺ and CD4⁺ T cells 10.1038/icb.2015.87

Author correction to "The Bordetella pertussis type III secretion system tip complex protein Bsp22 is not a protective antigen and fails to elicit serum antibody responses during infection of humans and mice" [Infect. Immun. 81, 8, (2013), 2761-2767] 10.1128/IAI.02017-14

Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines 10.1586/14760584.2014.944900

Calcium-Driven Folding of RTX Domain β-Rolls Ratchets Translocation of RTX Proteins through Type I Secretion Ducts 10.1016/j.molcel.2016.03.018

Bordetella pertussis adenylate cyclase toxin blocks induction of bactericidal nitric oxide in macrophages through cAMP-dependent activation of the SHP-1 phosphatase 10.4049/jimmunol.1402941

Differences in purinergic amplification of osmotic cell lysis by the pore-forming RTX toxins bordetella pertussis CyaA and actinobacillus pleuropneumoniae ApxIA: The role of pore size 10.1128/IAI.00711-13

Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells 10.1002/prot.24472

Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin 10.1016/j.antiviral.2012.09.008

Intrinsically disordered enamel matrix protein ameloblastin forms ribbon-like supramolecular structures via an N-terminal segment encoded by exon 5 10.1074/jbc.M113.456012

Increasing affinity of interferon- γ receptor 1 to interferon- γ by computer-aided design 10.1155/2013/752514

Biocompatible Size-Defined Dendrimer-Albumin Binding Protein Hybrid Materials as a Versatile Platform for Biomedical Applications 10.1002/mabi.201500332

The RNA chaperone Hfq is required for virulence of bordetella pertussis 10.1128/IAI.00345-13

Redesigning protein cavities as a strategy for increasing affinity in protein-protein interaction: Interferon-γ receptor 1 as a model 10.1155/2015/716945

Induction of protective immunity against Mycobacterium tuberculosis by delivery of ESX antigens into airway dendritic cells 10.1038/mi.2012.92

Interaction of Bordetella adenylate cyclase toxin with complement receptor 3 involves multivalent glycan binding 10.1016/j.febslet.2014.12.023

Proteome analysis of Bordetella pertussis isolated from human macrophages 10.1016/j.jprot.2016.02.002

Plasmodium berghei sporozoite challenge of vaccinated BALB/c mice leads to the induction of humoral immunity and improved function of CD8+ memory T cells 10.1002/eji.201142262

cAMP signalling of Bordetella adenylate cyclase toxin through the SHP-1 phosphatase activates the BimEL-Bax pro-apoptotic cascade in phagocytes 10.1111/cmi.12519

Hydrogen-oxidizing bacteria in biotechnology 10.1016/0167-7799(86)90184-8

Quantification of potassium levels in cells treated with Bordetella adenylate cyclase toxin 10.1016/j.ab.2013.10.039

Author correction to "The RNA chaperone Hfq is required for virulence of Bordetella pertussis" Infect. Immun [81, 11, (2013) 4081-4090] 10.1128/IAI.01944-14

Bordetella pertussis filamentous hemagglutinin itself does not trigger anti-inflammatory interleukin-10 production by human dendritic cells 10.1016/j.ijmm.2015.11.003

Filamentous hemagglutinin of Bordetella pertussis: A key adhesin with immunomodulatory properties? 10.2217/fmb.14.77

Bordetella adenylate cyclase toxin is a unique ligand of the integrin complement receptor 3 10.7554/eLife.10766

Antigen targeting to CD11b⁺ dendritic cells in association with TLR4/TRIF signaling promotes strong CD8⁺ T cell responses 10.4049/jimmunol.1302974

Bordetella adenylate cyclase toxin differentially modulates toll-like receptor-stimulated activation, migration and T cell stimulatory capacity of dendritic cells 10.1371/journal.pone.0104064

cAMP Signaling of Adenylate Cyclase Toxin Blocks the Oxidative Burst of Neutrophils through Epac-Mediated Inhibition of Phospholipase C Activity 10.4049/jimmunol.1601309

The conserved tyrosine residue 940 plays a key structural role in membrane interaction of Bordetella adenylate cyclase toxin 10.1038/s41598-017-09575-6

Phosphoproteomics of cAMP signaling of Bordetella adenylate cyclase toxin in mouse dendritic cells 10.1038/s41598-017-14501-x

Phospholipase A activity of adenylate cyclase toxin? 10.1073/pnas.1722588115

A novel "clip-and-link" activity of repeat in toxin (RTX) proteins from gram-negative pathogens: Covalent protein cross-linking by an Asp-Lys isopeptide bond upon calcium-dependent processing at an Asp-Pro bond 10.1074/jbc.M314013200

† 10.1021/bi050459b

Residues 529 to 549 participate in membrane penetration and pore-forming activity of the Bordetella adenylate cyclase toxin 10.1038/s41598-019-42200-2

Acylation of lysine 983 is sufficient for toxin activity of Bordetella pertussis adenylate cyclase. Substitutions of alanine 140 modulate acylation site selectivity of the toxin acyltransferase CyaC 10.1074/jbc.M006463200

Adenylate cyclase toxin translocates across target cell membrane without forming a pore 10.1111/j.1365-2958.2010.07077.x

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/IAI.74.4.2128-2137.2006

Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus 10.1073/pnas.94.7.3314

Bordetella adenylate cyclase toxin induces a cascade of morphological changes of sheep erythrocytes and localizes into clusters in erythrocyte membranes. 10.1002/jemt.20277

Bordetella adenylate cyclase toxin mobilizes its b2 integrin receptor into lipid rafts to accomplish translocation across target cell membrane in two steps 10.1371/journal.ppat.1000901

Bordetella adenylate cyclase toxin: A swift saboteur of host defense 10.1016/j.mib.2005.12.011

Bordetella protein toxins 10.1016/B978-012088445-2/50021-4

Calcium influx rescues adenylate cyclase-hemolysin from rapid cell membrane removal and enables phagocyte permeabilization by toxin pores 10.1371/journal.ppat.1002580

Channel formation in model membranes by the adenylate cyclase toxin of Bordetella pertussis: Effect of calcium 10.1021/bi034295f

Characterization of the flexible genome complement of the commensal Escherichia coli strain A0 34/86 (O83:K24:H31) 10.1099/mic.0.27469-0

Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid 10.1016/j.vaccine.2008.08.057

Complexes of Streptavidin-Fused Antigens with Biotinylated Antibodies Targeting Receptors on Dendritic Cell Surface: A Novel Tool for Induction of Specific T-Cell Immune Responses 10.1007/s12033-011-9459-6

Crystallization and preliminary crystallographic characterization of the iron-regulated outer membrane lipoprotein FrpD from Neisseria meningitidis 10.1107/S174430911003215X

Delineation of the minimal portion of the Bacillus sphaericus 1593M toxin required for the expression of larvicidal activity 10.1111/j.1432-1033.1990.tb19440.x

Delivery of large heterologous polypeptides across the cytoplasmic membrane of antigen-presenting cells by the Bordetella RTX hemolysin moiety lacking the adenylyl cyclase domain 10.1128/IAI.05711-11

Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity 10.1128/JVI.75.16.7330-7338.2001

Detection of immune cell response to M. tuberculosis-specific antigens by quantitative polymerase chain reaction 10.1016/j.diagmicrobio.2011.09.024

Different structural requirements for adenylate cyclase toxin interactions with erythrocyte and liposome membranes 10.1016/j.bbamem.2003.11.008

Editorial - ETOX turned twenty 10.1078/1438-4221-00308

Efficient ex vivo stimulation of Mycobacterium tuberculosis-specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids 10.1128/IAI.73.5.2991-2998.2005

Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T cells in human immunodeficiency virus-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector 10.1128/CVI.00041-07

Gliadin fragments promote migration of dendritic cells 10.1111/j.1582-4934.2010.01066.x

Hemolytic, but not cell-invasive activity, of adenylate cyclase toxin is selectively affected by differential fatty-acylation in Escherichia coli 10.1074/jbc.270.35.20250

Heterologous expression of full-length capsid protein of porcine circovirus 2 in Escherichia coli and its potential use for detection of antibodies 10.1016/j.jviromet.2009.07.028

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/IAI.02086-05

High-level synthesis of active adenylate cyclase toxin of Bordetella pertussis in a reconstructed Escherichia coli system 10.1016/0378-1119(91)90459-O

HlyA knock out yields a safer Escherichia coli A0 34/86 variant with unaffected colonization capacity in piglets 10.1111/j.1574-695X.2006.00140.x

Identification by in vitro complementation of regions required for cell-invasive activity of Bordetella pertussis adenylate cyclase toxin 10.1111/j.1365-2958.1995.mmi_17061015.x

Identification of an inducible penicillinase of the lithoautotrophic hydrogen-oxidizing bacterium Alcaligenes eutrophus 10.1007/BF02887567

Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria 10.1128/IAI.74.4.2277-2285.2006

In vitro activation of CMV-specific human CD8 T cells by adenylate cyclase toxoids delivering pp65 epitopes 10.1038/bmt.2011.68

In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying multiple copies of a viral CD8 + T-cell epitope 10.1016/S0928-8244(99)00137-6

Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis 10.1128/IAI.68.7.3867-3872.2000

Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis 10.4049/jimmunol.1000105

Integrin Subunit CD18 Is the T-Lymphocyte Receptor for the Helicobacter pylori Vacuolating Cytotoxin 10.1016/j.chom.2007.11.003

Interaction of Bordetella pertussis adenylate cyclase with CD11b/CD18. Role of toxin acylation and identification of the main integrin interaction domain 10.1074/jbc.M304387200

Interaction of calcium with Bordetella pertussis adenylate cyclase toxin. Characterization of multiple calcium-binding sites and calcium-induced conformational changes 10.1074/jbc.270.44.26370

Membrane restructuring by Bordetella pertussis adenylate cyclase toxin, a member of the RTX toxin family 10.1128/JB.186.12.3760-3765.2004

Meningococcal adhesion suppresses proapoptotic gene expression and promotes expression of genes supporting early embryonic and cytoprotective signaling of human endothelial cells 10.1111/j.1574-6968.2006.00407.x

Molecular properties of elongation factor Tu from Streptomyces aureofaciens and Escherichia coli 10.1007/BF02928072

Neisseria meningitidis RTX protein FrpC induces high levels of serum antibodies during invasive disease: Polymorphism of frpC alleles and purification of recombinant FrpC 10.1128/IAI.69.9.5509-5519.2001

Neisseria meningitidis RTX proteins are not required for virulence in infant rats 10.1128/IAI.71.4.2253-2257.2003

Neisseria meningitidisFrpC 10.1110/ps.035733.108

Nematode-induced interference with the anti-Plasmodium CD8 + T-cell response can be overcome by optimizing antigen administration 10.1002/eji.201141955

Novel high-affinity binders of human interferon gamma derived from albumin-binding domain of protein G 10.1002/prot.23234

Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases 10.1006/jaut.2000.0452

Oligomerization is involved in pore formation by Bordetella adenylate cyclase toxin 10.1096/fj.09-131250

On the respective roles of the two proteins encoded by the Bacillus sphaericus 1593M toxin genes expressed in Escherichia coli and Bacillus subtilis 10.1016/0006-291X(89)91828-7

Pore formation by the Bordetella adenylate cyclase toxin in lipid bilayer membranes: Role of voltage and pH 10.1016/j.bbamem.2007.09.026

Pore-forming and enzymatic activities of Bordetella pertussis adenylate cyclase toxin synergize in promoting lysis of monocytes 10.1128/IAI.74.4.2207-2214.2006

Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara 10.1007/s00262-005-0700-7

RTX cytotoxins recognize β2 integrin receptors through N-linked oligosaccharides 10.1073/pnas.0711400105

RTX proteins: A highly diverse family secreted bya common mechanism 10.1111/j.1574-6976.2010.00231.x

Recognition of mycobacterial antigens delivered by genetically detoxified Bordetella pertussis adenylate cyclase by T cells from cattle with bovine tuberculosis 10.1128/IAI.72.11.6255-6261.2004

Segments crucial for membrane translocation and pore-forming activity of Bordetella adenylate cyclase toxin 10.1074/jbc.M611226200

Sensitive detection of interferon-gamma with engineered proteins and surface plasmon resonance biosensor 10.1016/j.proeng.2011.12.231

Specific regions of genome plasticity and genetic diversity of the commensal Escherichia coli A0 34/86 10.1016/j.ijmm.2006.06.007

The Neisseria meningitidis outer membrane lipoprotein FrpD binds the RTX protein FrpC 10.1074/jbc.M411232200

The adenylate cyclase toxin from Bordetella pertussis - A novel promising vehicle for antigen delivery to dendritic cells 10.1078/1438-4221-00291

The conserved lysine 860 in the additional fatty-acylation site of Bordetella pertussis adenylate cyclase is crucial for toxin function independently of its acylation status 10.1074/jbc.274.16.10777

The iron-regulated transcriptome and proteome of Neisseria meningitidis serogroup C 10.1002/pmic.200600312

Third activity of Bordetella adenylate cyclase (AC) toxin-hemolysin: Membrane translocation of AC domain polypeptide promotes calcium influx into CD11b + monocytes independently of the catalytic and hemolytic activities 10.1074/jbc.M609979200

Transmission of Mycobacterium tuberculosis undetected by tuberculin skin testing 10.1164/rccm.200509-1526OC

Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia 10.1186/1297-9716-43-2

Rapid Purification of Endotoxin-Free RTX Toxins 10.3390/toxins11060336

Distinct Spatiotemporal Distribution of Bacterial Toxin-Produced Cellular cAMP Differentially Inhibits Opsonophagocytic Signaling 10.3390/toxins11060362

Cytotoxicity of the effector protein BteA was attenuated in Bordetella pertussis by insertion of an alanine residue 10.1101/2020.04.03.023549

Retargeting from the CR3 to the LFA-1 receptor uncovers the adenylyl cyclase enzyme–translocating segment of Bordetella adenylate cyclase toxin 10.1074/jbc.RA120.013630

Acyltransferase-mediated selection of the length of the fatty acyl chain and of the acylation site governs activation of bacterial RTX toxins 10.1074/jbc.RA120.014122

Bordetella pertussis Acetylome is Shaped by Lysine Deacetylase Bkd1 10.1021/acs.jproteome.0c00178

Cytotoxicity of the effector protein BteA was attenuated in Bordetella pertussis by insertion of an alanine residue 10.1371/journal.ppat.1008512

Production of Highly Active Recombinant Dermonecrotic Toxin of Bordetella Pertussis 10.3390/toxins12090596

Acellular Pertussis Vaccine Inhibits Bordetella pertussis Clearance from the Nasal Mucosa of Mice 10.3390/vaccines8040695